Navigation Links
Antidepressant Effectiveness Probably Overstated: Report
Date:1/16/2008

Researchers unclear on whether it's reluctance to submit or reluctance to publish negative findings

WEDNESDAY, Jan. 16 (HealthDay News) -- A systematic review of studies on antidepressants concludes that the positive effects of these drugs are probably overstated in the medical literature.

But it's not clear if the bias comes from a reluctance to submit negative manuscripts or decisions by journals not to publish them, or a combination of both, according to Oregon Health and Science University researchers, whose report is published in the Jan. 17 issue of the New England Journal of Medicine.

The researchers compared drug efficacy inferred from published studies with drug efficacy reported to a mandatory U.S. government registry of clinical trials, in which all results, including raw data, must be included.

Only 51 percent of studies in the U.S. Food and Drug Administration registry were considered by the agency to have positive results.

In the published medical literature, however, 94 percent of studies appeared positive.

The increase in the effectiveness of the drug ranged from 11 percent to 69 percent for individual drugs, and was 32 percent overall. The antidepressant Wellbutrin appeared to show a high level of bias.

The authors also noted that studies that were not positive were often published with a slant that made them seem positive.

"For the average patient, yes, these drugs are effective, just less effective than they appear," said study author Dr. Erick Turner, an assistant professor of psychiatry and pharmacology at Oregon Health Sciences University. "Don't be overly disappointed if you don't have an excellent response to the first antidepressant you try. You might have to try two or three, and you might need to add psychotherapy."

One expert hailed the finding.

"This is, in my opinion, an excellent paper and what it shows is really consistent with the past five years," said Adil Shamoo, founder of Citizens for Responsible Care and Research and a professor of biochemistry and molecular biology at the University of Maryland School of Medicine in Baltimore. "Publications have indicated that [the] industry basically has a tendency to bias publications towards positive results and to not publish negative results."

"Research is not regulated by anyone, so therefore they don't have to submit to anyone, and that's really the key," Shamoo added. "It's a systemic failure."

Other experts presented slightly differing points of view.

"It's not that the drugs are ineffective, but that the public's perception is that they are more effective than they are [something the authors also point out]," said Dr. Julio Licinio, chairman of psychiatry and behavioral sciences at the University of Miami Miller School of Medicine. "The data was good enough for the drugs to get approval."

"The concern that selective publication of clinical studies routinely overestimates the benefit of medical services is not new," added Dr. A. Mark Fendrick, a professor of internal medicine and health management and policy at the University of Michigan. "While the creation of clinical trial registries will enhance access to unpublished data, the availability of information alone will likely not be very useful to patients and clinicians unless the results can be analyzed in a careful manner, as performed in this important study."

The buzzword in health care these days is "evidence-based medicine," meaning therapies and preventive strategies that are based on careful, scientific evidence as reported in clinical trials.

However, the study authors pointed out, such evidence-based practices are helpful only insofar as the data available is complete and unbiased.

And, they said, it is difficult to study "selective publication" primarily because data from unpublished trials is hard to locate.

"Pharmaceutical companies have responded to the heat," Turner said. "[But] it's hidden under our very noses."

For example, as a result of a 2004 lawsuit, GlaxoSmithKline initiated a clinical trial registry. "I have yet to speak to a colleague who knew about that," Turner said, adding that physicians generally look to peer-reviewed journals for guidance.

Licinio believes the reasons for the bias are a combination of people not submitting papers and editors/publishers not printing them. As the editor of the journal Molecular Psychiatry, Licinio receives more than 700 submissions a year and publishes an average of 144. "It becomes very difficult to select," he said.

"There should be a national repository for these kinds of reports [that don't get published in journals]," Licinio added. "Those papers don't see the light of day."

More information

The FDA has more on safety issues related to the use of antidepressants.



SOURCES: Erick Turner, M.D., assistant professor, psychiatry and pharmacology, Oregon Health Sciences University, and medical director, mood disorders, Portland VA; Adil Shamoo, Ph.D., founder, Citizens for Responsible Care and Research, and professor, biochemistry and molecular biology, University of Maryland School of Medicine, Baltimore; Julio Licinio, M.D., professor and chairman, psychiatry and behavioral sciences, University of Miami Miller School of Medicine, and editor, Molecular Psychiatry; Mark Fendrick, M.D., professor, internal medicine and health management and policy, University of Michigan, Ann Arbor; Jan. 17, 2008, New England Journal of Medicine


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Youth Suicide Warnings Are Slowing Antidepressant Sales
2. Antidepressants Help HIV-Infected Patients Stick to Treatment
3. Natural human hormone as the next antidepressant?
4. Study shows new strategy for developing antidepressants
5. Marijuana-like brain chemicals work as antidepressant
6. Antidepressants Boost GI Bleeding Risk
7. Antidepressants and painkillers - a dangerous combination
8. Genetic test announced for suicidal ideation in patients using antidepressant drugs
9. Genes Might Predispose Antidepressant Users to Suicidal Thoughts
10. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
11. Antidepressant as Good as Antipsychotics for Dementia
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 Antidepressant Effectiveness Probably Overstated: Report
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users ... - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 ... Pro X . Simply select a ProHand generator and drag it above media or ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets has ... Market Analysis 2016 - Forecast to 2022" report to ... report contains up to date financial data derived from varied ... major trends with potential impact on the market during the ... segmentation which comprises of sub markets, regional and country level ...
(Date:6/23/2016)... , June 23, 2016 , ... Thursday, July 7, 2016 , , , , LOCATION: , ... , , , , EXPERT PANELISTS:  , , , Frost ... Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh ... The global pharmaceutical industry is witnessing an exceptional era. Several ...
(Date:6/23/2016)... 23, 2016  Guerbet announced today that it has ... Horizon Award . One of 12 suppliers ... for its support of Premier members through exceptional local ... and commitment to lower costs. ... of our outstanding customer service from Premier," says ...
Breaking Medicine Technology: